ArticleArthritis & rheumatology (Hoboken, N.J.)2019

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.

Christina Charles-Schoeman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.